AnaptysBio Executive Compensation Revealed
Ticker: ANAB · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1370053
| Field | Detail |
|---|---|
| Company | Anaptysbio, Inc (ANAB) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, governance
TL;DR
AnaptysBio dropped its proxy statement detailing exec pay for 2024 - check out those equity awards!
AI Summary
AnaptysBio, Inc. filed its DEF 14A on April 29, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to its principal executive officer (PEO) and non-PEO named executive officers, as well as compensation details for non-employee directors. Specific figures for stock option grants and year-end valuations of outstanding equity awards are provided.
Why It Matters
This filing provides transparency into how AnaptysBio compensates its top executives and directors, which can influence investor decisions and perceptions of company governance.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the details on executive compensation can sometimes reveal potential governance issues or significant changes in pay structure that could impact investor sentiment.
Key Numbers
- 2024 — Fiscal Year (Period covered by the compensation data)
- 20250429 — Filing Date (Date the DEF 14A was submitted to the SEC)
Key Players & Entities
- ANAPTYSBIO, INC (company) — Filer of the DEF 14A
- 20250429 (date) — Filing date of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for compensation details
- Daniel Faga (person) — Named executive officer
- Hamza Suria (person) — Named executive officer
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to disclose information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation, director nominations, and other corporate governance matters.
Who are the named executive officers mentioned in relation to equity awards for the fiscal year 2024?
The filing references equity awards for the PEO (Principal Executive Officer) and Non-PEO Named Executive Officers, with specific individuals like Daniel Faga and Hamza Suria noted in relation to compensation data for 2022.
What types of equity awards are detailed in the filing?
The filing details equity awards granted in covered years, including stock option grants and year-end valuations of outstanding and unvested equity awards for both PEO and Non-PEO members.
What is the company's fiscal year end?
AnaptysBio, Inc.'s fiscal year ends on December 31st.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 29, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 by Daniel Faga regarding ANAPTYSBIO, INC (ANAB).